Safety and 5-year survival following treatment with leronlimab plus physician’s choice combination therapy in patients with metastatic triple-negative breast cancer.
https://www.asco.org/abstracts-presentations/263424
Leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study.
https://www.asco.org/abstracts-presentations/262713
The full abstract texts will be available on May 21 at 05:00 PM EST
Dr. Kasi is shown for mCRC.
Dr. Debasish Tripathy is shown for mTNBC. He is Professor and Chair of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center. There are 11 names listed at the top of the recent mTNBC poster but none are from MD Anderson. Nice to see their involvement here.